Inactive Instrument

Medipharm Labs Corp Share Price Toronto S.E.

Equities

Pharmaceuticals

End-of-day quote Toronto S.E.
- CAD - Intraday chart for Medipharm Labs Corp
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 43.84M 31.83M 2.5B Sales 2025 * 54.94M 39.88M 3.14B Capitalization 30.37M 22.05M 1.73B
Net income 2024 * -8M -5.81M -457M Net income 2025 * -3M -2.18M -171M EV / Sales 2024 * 0.69 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 0.55 x
P/E ratio 2024 *
-3.75 x
P/E ratio 2025 *
-7.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.47%
More Fundamentals * Assessed data
Transcript : MediPharm Labs Corp., Q1 2024 Earnings Call, May 15, 2024
MediPharm Labs Q1 Gross Profit, Rise MT
MediPharm Labs Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
MediPharm Labs Corp. Brief: Anticipates further improvement on profitability in 2024 with plans being implemented to improve Adjusted EBITDA by a further $1-$2 Million MT
MediPharm Labs Corp. Brief: Revenue increased 67% to $9.8 Million during the three months ended March 31, 2024, versus revenue for the same quarter in 2023 of $5.8 Million MT
MediPharm Labs Narrows Q4 Loss, Revenue Grows; Up 10.5% MT
MediPharm Labs Narrows Q4 Loss, Revenue Grows MT
Transcript : MediPharm Labs Corp., Q4 2023 Earnings Call, Mar 27, 2024
MediPharm Labs Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
MediPharm Labs Corp. Brief: Q4 Revenue $9.131 Million; Says Annual Revenue and Adjusted EBITDA Improve by 50% MT
MediPharm Labs Offers Update on German Cannabis Legalization; Up Nearly 6% MT
IM Cannabis Corp. Brief: Notes This Provides IMC Germany with a "Unique Opportunity" to further accelerate growth in 2024 after delivering 180% growth in 2023 MT
IM Cannabis Corp. Brief: Adds By rescheduling medical cannabis, from a narcotic to a regular prescription, the German medical cannabis market is Expected to deliver "Strong" growth MT
IM Cannabis Corp. Brief: Says Expects "Accelerated Growth" in Germany from that Country's "Groundbreaking" Cannabis Legalization MT
MediPharm Labs Offers Update on German Cannabis Legalization MT
More news
Managers TitleAgeSince
Chief Executive Officer - 19/04/22
Director of Finance/CFO - 07/02/21
President - 30/09/18
Members of the board TitleAgeSince
Director/Board Member 60 31/03/23
Chief Executive Officer - 19/04/22
Director/Board Member - 21/06/20
More insiders
MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. The Company's subsidiary, Harvest Medicine provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW